By Long Tran, Pharm D; Beckie Fenrick, Pharm D; and Jason Peterson, RPh
HIV prevention and treatment options are expanding quickly, giving members more ways to prevent transmission and maintain viral suppression. But for plan sponsors, that growth brings new complexity around coverage, access, adherence and cost.
As oral, injectable, branded, generic and pipeline therapies reshape the market, employers, brokers and TPAs need a pharmacy strategy that supports appropriate access without losing sight of spend. Here’s what to know about the evolving HIV treatment and PrEP landscape.
Understanding HIV PrEP and HIV Treatment
HIV-related medications are generally used for two purposes: PrEP to prevent HIV transmission and antiretroviral therapy, or ART, to treat HIV infection.
PrEP can reduce the risk of contracting HIV by up to 99%, but adherence is essential. Route of administration, dosing frequency, access and affordability all affect whether members stay on therapy, which may make long-acting injectable options helpful for some patients.
For individuals living with HIV, ART remains the standard of care and should begin as soon as possible after diagnosis. Most regimens combine multiple drug classes, often in a single daily pill, though long-acting injectable therapies may also be available.
For plan sponsors, supporting appropriate access matters clinically and financially. Preventing HIV is far less expensive than treating an active infection, making benefit design an important part of both prevention and long-term cost management.
HIV PrEP and Pharmacy Trend Impact
PrEP has become an important part of HIV prevention strategy, with options now spanning daily oral therapies and long-acting injectables.
There are four FDA-approved PrEP treatments: two oral formulations and two injectables.
| Medication | Administration/Frequency | Generic Availability | Estimated Annual Cost |
| Truvada (emtricitabine/tenofovir disoproxil fumarate) | Oral tablet taken daily | Yes | $22,414 |
| Emtricitabine/tenofovir disoproxil fumarate, generic Truvada | Oral tablet taken daily | — | $2,472 to $8,678 |
| Descovy (emtricitabine/tenofovir alafenamide) | Oral tablet taken daily | 2031 | $26,795 |
| Apretude (cabotegravir) | Injection every 2 months | 2031 | $25,374 |
| Yeztugo (lenacapavir) | Injection every 6 months | 2040 | $28,218 |
Based on the United States Preventive Services Task Force Grade A evidence rating, the Affordable Care Act requires most prescription benefit plans to cover HIV PrEP with no cost to patients.
In October 2024, the Department of Labor clarified that plans may use reasonable medical management for PrEP when USPSTF recommendations do not specify frequency, method, treatment, or setting. However, the current 2023 USPSTF PrEP recommendations identify three FDA-approved PrEP formulations. As a result, plans must cover the formulations specified in the recommendation without cost sharing and may not steer members toward one formulation over another.
HIV Treatment Options and Plan Sponsor Considerations
A broad array of HIV therapies is available. Treatment selection is highly individualized and may depend on comorbid conditions, drug-drug interactions, side-effect profiles, resistance patterns and adherence considerations.
The medications below may have meaningful implications for pharmacy benefit strategy:
| Medication | Dosing Frequency | Estimated Annual Cost | Plan Sponsor Consideration |
| Cabenuva | Injection every 1–2 months | $42,798 | Long-acting option for members with adherence challenges; high cost and provider-administered dosing may require careful benefit design. |
| Sunlenca | Injection every 6 months | $39,000 | Typically reserved for heavily treatment-experienced adults with limited remaining options. |
| Biktarvy | Single pill taken once daily | $51,296 | Common first-line option with strong efficacy, tolerability and resistance profile. |
| Dovato | Single pill taken once daily | $39,547 | Two-drug, single-tablet regimen that offers an alternative to traditional three-drug regimens for appropriate patients |
| Tivicay | Taken once daily or twice daily | $29,138 | Typically used with other antiretroviral therapies; may face generic competition by 2028. |
| Triumeq | Single pill taken once daily | $48,841 | Remains a first-line option, though use has declined due to abacavir-related hypersensitivity risk. |
| Genvoya | Single pill taken once daily | $53,809 | Four-drug single-tablet option, often used as an alternative to other first-line regimens. |
| Juluca | Single pill taken once daily | $45,775 | Switch option for virologically suppressed patients with no treatment failure or relevant resistance history. |
| Odefsey | Single pill taken once daily | $48,971 | Used in select clinical scenarios, including some stable patients transitioning from another regimen. |
| Symtuza | Single pill taken once daily | $57,389 | Complete regimen for certain new-to-therapy or virologically suppressed patients. |
| Idvynso | Single pill taken once daily | $54,203 | Two drug regimen for certain patients who need an alternative to common regimens that include integrase inhibitors or tenofovir. |
Note: Dosing frequencies reflect adult HIV treatment recommendations and are provided for educational purposes only. Please refer to official prescribing information for complete dosing details. HIV treatment decisions should be made with a qualified healthcare provider based on each patient’s clinical circumstances.
Practical Takeaways for Plan Sponsors
HIV treatment and PrEP continue to evolve rapidly, with newer therapies, long-acting options and additional prevention products reshaping the market. For plan sponsors, the challenge is balancing cost management with appropriate access, adherence and continuity of care.
Point solutions such as manufacturer copay assistance, patient assistance navigation, specialty pharmacy support and international sourcing programs may help reduce plan and/or patient costs for some products. However, these programs must be implemented carefully to avoid delays in access.
The goal is not simply to reduce drug spend, but to support clinically appropriate therapy, maintain treatment stability and manage long-term pharmacy costs without creating unnecessary barriers to care.
Need help evaluating how evolving therapies may affect your pharmacy benefit strategy? Navion helps organizations assess clinical trends, identify cost-management opportunities and support sustainable pharmacy benefit management.
